<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:media="http://search.yahoo.com/mrss/"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>foregoes &#8211; USA NEWS LIVE</title>
	<atom:link href="https://bloggingthree.soflytech.com/tag/foregoes/feed/" rel="self" type="application/rss+xml" />
	<link>https://bloggingthree.soflytech.com</link>
	<description>All About USA NEWS</description>
	<lastBuildDate>Sun, 22 Sep 2024 20:07:59 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.4</generator>

<image>
	<url>https://bloggingthree.soflytech.com/wp-content/uploads/2024/04/cropped-THE-USA1-e1713184454543-1-32x32.png</url>
	<title>foregoes &#8211; USA NEWS LIVE</title>
	<link>https://bloggingthree.soflytech.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Walmart plans quick bank payments, foregoes card networks – The Mercury News</title>
		<link>https://bloggingthree.soflytech.com/2024/09/walmart-plans-quick-bank-payments-foregoes-card-networks-the-mercury-news/</link>
		
		<dc:creator><![CDATA[chandankumarsoft]]></dc:creator>
		<pubDate>Sun, 22 Sep 2024 20:07:59 +0000</pubDate>
				<category><![CDATA[Technology]]></category>
		<category><![CDATA[bank]]></category>
		<category><![CDATA[card]]></category>
		<category><![CDATA[foregoes]]></category>
		<category><![CDATA[instant]]></category>
		<category><![CDATA[Mercury]]></category>
		<category><![CDATA[networks]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[payments]]></category>
		<category><![CDATA[plans]]></category>
		<category><![CDATA[Walmart]]></category>
		<guid isPermaLink="false">https://bloggingthree.soflytech.com/?p=15483</guid>

					<description><![CDATA[Walmart Inc. customers will soon give you the option to pay for online purchases directly from their bank accounts using quick bank transfers. The expanded feature is a flashpoint in escalating tensions between retailers and the cardboard networks that set payment processing fees. The world&#39;s largest retailer began offering wire transfer payments through Walmart Pay [&#8230;]]]></description>
										<content:encoded><![CDATA[<p><img decoding="async" src="https://www.mercurynews.com/wp-content/uploads/2024/09/BIZ-WALMART-INSTANT-BANK-PAYMENTS-GET.jpg?w=1400px&amp;strip=all" /></p>
<div>
<p>Walmart Inc. customers will soon give you the option to pay for online purchases directly from their bank accounts using quick bank transfers. The expanded feature is a flashpoint in escalating tensions between retailers and the cardboard networks that set payment processing fees.</p>
<p>The world&#39;s largest retailer began offering wire transfer payments through Walmart Pay earlier this yr. Until now, transactions resembled digital checks and took about three days to clear through The Automated Clearing House, the identical network often used for bill payments or payroll deposits. Soon, customers who decide to pay by wire transfer will see the acquisition reflected of their checking account balance immediately &#8211; and Walmart will receive the cash immediately.</p>
<p>The consumer advantage of quick bank payment over debit cards is that there aren&#8217;t any ongoing pending transactions. According to Jamie Henry, vice chairman of recent payment methods at Walmart, pending transactions can put customers with low balances vulnerable to overdraft or non-funding fees from their bank.</p>
<p>&#8220;When the transaction is processed as a real-time payment, customers can see immediately that the payment has been received. I see that it has hit my account and can plan my budget accordingly,&#8221; Henry said. &#8220;It&#39;s not like I have this phantom payment that&#39;s not due for a few days.&#8221;</p>
<p>In the U.S., most consumers have credit or debit cards, which supply convenience, fraud protection and, within the case of credit products, rewards programs. However, frustration has grown amongst merchants over the fees they pay to banks and networks like Visa and Mastercard for card processing. At the identical time, consumers are upset because some merchants pass these fees on to them in the shape of surcharges. As frustration over card fees grows and more banks use real-time systems, alternative payment methods like pay-by-bank have a probability to realize ground.</p>
<p>&#8220;It surprised me,&#8221; Henry said of Walmart&#39;s launch of its first version of the &#8220;by bank&#8221; payment method, which is accessible online but has not yet been marketed to customers. &#8220;It has definitely exceeded our expectations in terms of the number of customers who have signed up and are actually using this payment method.&#8221;</p>
<p>&#8220;As an industry, we believe we need to create that connectivity,&#8221; said Matt Wilcox, head of digital payments at Fiserv. &#8220;FedNow and RTP don&#39;t necessarily talk to each other. The NOW Network can play that role in the industry by bringing all of those networks together to enable applications like paying by bank.&#8221;</p>
<p>The quick bank transfer payment product shall be available for online checkout on Walmart.com. The Bentonville, Arkansas-based retailer already has its customers arrange a profile after they shop online. If they select so as to add bank transfer payment as a payment option of their profile, they enter their bank credentials to attach their account. Fiserv&#39;s AllData platform connects with its banking customers and suppliers, including Plaid, MX, Akoya and Finicity, to link and authenticate consumer accounts.</p>
<p>___</p>
<p>©2024 Bloomberg LP Visit <a href="https://www.bloomberg.com/">bloomberg.com.</a> Distributed by Tribune Content Agency, LLC.</p>
<p>Originally published: <time datetime="2024-09-20 11:28:18">September 20, 2024 at 11:28 am</time></p>
</div>
<p><em>image credit : www.mercurynews.com</em></p>
]]></content:encoded>
					
		
		
		<media:content url="https://www.mercurynews.com/wp-content/uploads/2024/09/BIZ-WALMART-INSTANT-BANK-PAYMENTS-GET.jpg?w=1024&#038;h=682" medium="image"></media:content>
	</item>
		<item>
		<title>Amgen foregoes experimental weight reduction pill and pushes ahead with injection</title>
		<link>https://bloggingthree.soflytech.com/2024/05/amgen-foregoes-experimental-weight-reduction-pill-and-pushes-ahead-with-injection/</link>
		
		<dc:creator><![CDATA[chandankumarsoft]]></dc:creator>
		<pubDate>Fri, 03 May 2024 07:26:35 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[ahead]]></category>
		<category><![CDATA[Amgen]]></category>
		<category><![CDATA[experimental]]></category>
		<category><![CDATA[foregoes]]></category>
		<category><![CDATA[injection]]></category>
		<category><![CDATA[loss]]></category>
		<category><![CDATA[pill]]></category>
		<category><![CDATA[pushes]]></category>
		<category><![CDATA[weight]]></category>
		<guid isPermaLink="false">https://bloggingthree.soflytech.com/?p=2389</guid>

					<description><![CDATA[Amgen announced Thursday that it could stop development of its experimental weight-loss pill and as a substitute proceed development of its injectable drug and other anti-obesity products in development. Amgen is one in every of several drugmakers vying to enter the red-hot weight-loss drug space dominated by Novo Nordisk And Eli Lilly, which some analysts [&#8230;]]]></description>
										<content:encoded><![CDATA[<p></p>
<div id="RegularArticle-ArticleBody-5" data-module="ArticleBody" data-test="articleBody-2" data-analytics="RegularArticle-articleBody-5-2"><span class="HighlightShare-hidden" style="top:0;left:0"></span></p>
<div class="group">
<p><span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-1">Amgen<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>    announced Thursday that it could stop development of its experimental weight-loss pill and as a substitute proceed development of its injectable drug and other anti-obesity products in development.</p>
<p>Amgen is one in every of several drugmakers vying to enter the red-hot weight-loss drug space dominated by <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-2">Novo Nordisk<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>    And <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-3">Eli Lilly<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>, which some analysts say could possibly be price $100 billion by the tip of the last decade.  But the corporate also has other ways to capture a part of the market.</p>
<p>“Given the profile we’ve seen [the oral drug]We will not follow any further developments.  Instead, we are making differentiated investments in MariTide and a number of preclinical products in the obesity space,” Amgen Chief Scientific Officer Jay Bradner said during a conference call Thursday.</p>
<p>Amgen is developing an injectable anti-obesity drug called MariTide, which is in an ongoing mid-stage trial in obese or obese adults without diabetes.  The company will release initial data from this study later this yr, and Bradner said Amgen is &#8220;very pleased&#8221; with the outcomes thus far. </p>
<p>The company said it&#8217;s working with regulators to plan a late-stage trial for the treatment.  Amgen said Thursday that additionally it is planning a Phase 2 trial of the drug to treat diabetes.</p>
<p>Amgen shares rose greater than 10% in prolonged trading Thursday following the comment on MariTide.</p>
<p>Amgen can also be developing other weight management drugs. </p>
<p>The drugmaker&#39;s oral drug, called AMG-786, is the second weight-loss pill to be discontinued previously yr.</p>
<p>Pfizer scrapped a twice-daily version of its obesity pill danuglipron in December after patients in a mid-stage trial had difficulty tolerating the drug.  The company is currently developing a once-daily version of this medication.</p>
<p>Investors are fully focused on Amgen&#39;s pipeline of experimental weight reduction treatments.  Amgen hopes to make use of a distinct approach to face out from the crowded field of potential players. </p>
<p>The company&#39;s experimental injection helps people reduce weight otherwise than existing injectable medications.  Similar to Novo Nordisk&#39;s Wegovy and Eli Lilly&#39;s Zepbound, a part of Amgen&#39;s treatment prompts a gut hormone receptor called GLP-1 to manage an individual&#39;s appetite. </p>
<p>But while Zepbound prompts a second hormone receptor called GIP, Amgen&#39;s drug blocks it.  Wegovy doesn&#8217;t goal GIP, which like GLP-1 suppresses appetite, but might also improve the way in which the body breaks down sugar and fat.</p>
<p>According to some clinical trial data, Amgen&#39;s injectable treatment also appears to assist patients reduce their weight after they stop taking it.  The drugmaker can also be testing that its drug ought to be taken once a month and even less often, which could provide more convenience than weekly medications available on the market. </p>
<p>Patients given the very best dose of Amgen&#39;s MariTide &#8211; 420 milligrams &#8211; every month lost a median of 14.5% of their body weight in only 12 weeks <a href="https://www.nature.com/articles/s42255-023-00966-w.pdf" target="_blank" rel="noopener">Data from the phase 1 study</a> published in February within the journal Nature Metabolism. </p>
</div>
<h2 class="ArticleBody-subtitle"><a id="headline0"></a>Amgen&#39;s first quarter results</h2>
<div class="group">
<p>Also on Thursday, Amgen reported first-quarter sales and adjusted earnings that beat Wall Street expectations, thanks partly to products from recently acquired Horizon Therapeutics. </p>
<p>Here&#39;s what Amgen reported for the primary quarter in comparison with Wall Street&#39;s expectations, based on an LSEG analyst survey:</p>
<ul>
<li><strong>Earnings per share:</strong> $3.96 versus expected $3.87</li>
<li><strong>Revenue:</strong> $7.45 billion versus expected $7.44 billion</li>
</ul>
<p>Amgen posted a net lack of $113 million, or 21 cents per share.  In comparison, net income within the year-ago period was $2.84 billion, or $5.28 per share.</p>
<p>Excluding certain items, the corporate reported profit of $3.96 per share. </p>
<p>Amgen posted first-quarter revenue of $7.45 billion, up 22% from the identical period last yr. </p>
<p>This includes $914 million from Horizon Therapeutics products, including Tepezza for the treatment of thyroid eye disease. </p>
<p>Excluding Horizon Therapeutics&#39; drugs, Amgen said its product sales rose 6% in comparison with the identical period last yr.  Ten products achieved double-digit volume growth in the primary quarter, including the cardiovascular drug Repatha, the severe asthma treatment Tezspire and Blincyto, a drug used to treat a certain blood cancer.</p>
<p>Amgen also adjusted its forecast for the total yr barely upwards from its low point on Thursday. </p>
<p>The company expects revenue of $32.5 billion to $33.8 billion in 2024.  That compares with a previous forecast of $32.4 billion to $33.8 billion. </p>
<p>Amgen expects full-year adjusted earnings of $19 to $20.20 per share.  This compares to previous guidance of $18.90 to $20.30 per share. </p>
<p>Analysts surveyed by LSEG expect full-year revenue of $32.95 billion and adjusted earnings of $19.48 per share. </p>
</div>
<div class="group">
<div class="RelatedContent-relatedContent" id="RegularArticle-RelatedContent-1">
<div class="RelatedContent-container">
<div class="RelatedContent-nonCollapsibleContent">
<h2 class="RelatedContent-header">Don&#39;t miss these exclusives from CNBC PRO</h2>
</div>
</div>
</div>
</div>
</div>
<p><em>image credit : www.cnbc.com</em></p>
]]></content:encoded>
					
		
		
		<media:content url="https://image.cnbcfm.com/api/v1/image/107243224-1684411224877-gettyimages-1491059980-mt_15744_opmy4ayv.jpeg?v=1714684125&#038;w=1920&#038;h=1080" medium="image"></media:content>
	</item>
		<item>
		<title>USC foregoes graduation performances after dropping Muslim speakers</title>
		<link>https://bloggingthree.soflytech.com/2024/04/usc-foregoes-graduation-performances-after-dropping-muslim-speakers/</link>
		
		<dc:creator><![CDATA[chandankumarsoft]]></dc:creator>
		<pubDate>Sat, 20 Apr 2024 09:23:35 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<category><![CDATA[dropping]]></category>
		<category><![CDATA[foregoes]]></category>
		<category><![CDATA[graduation]]></category>
		<category><![CDATA[Muslim]]></category>
		<category><![CDATA[performances]]></category>
		<category><![CDATA[speakers]]></category>
		<category><![CDATA[USC]]></category>
		<guid isPermaLink="false">https://bloggingthree.soflytech.com/?p=994</guid>

					<description><![CDATA[Associated Press LOS ANGELES (AP) — The University of Southern California further modified its commencement plans Friday, announcing the cancellation of a keynote address by filmmaker Jon M. Chu, just days after it made the controversial decision to ban the valedictorian from speaking. The private university in Los Angeles said Monday that it had canceled [&#8230;]]]></description>
										<content:encoded><![CDATA[<p><img decoding="async" src="https://www.mercurynews.com/wp-content/uploads/2024/04/sjm-eech-Canceled_187709719.jpg?w=1400px&amp;strip=all" /></p>
<div>
<p><strong>Associated Press</strong></p>
<p>LOS ANGELES (AP) — The University of Southern California further modified its commencement plans Friday, announcing the cancellation of a keynote address by filmmaker Jon M. Chu, just days after it made the controversial decision to ban the valedictorian from speaking.</p>
<p>The private university in Los Angeles said Monday that it had canceled valedictorian Asna Tabassum&#39;s speech on the May 10 ceremony for security reasons.  Tabassum, a Muslim, has voiced her support for Palestinians in the continuing Israel-Hamas war, and university officials said the response to her election as valedictorian has &#8220;taken on an alarming tone.&#8221;  They didn&#8217;t mention any specific threats.</p>
<p>The university&#39;s decision was praised by pro-Israel organizations but condemned by free speech groups and the Council on American-Islamic Relations.  Students and college marched across campus Thursday in silent protest against the university&#39;s decision.</p>
<p>Now university officials say they&#8217;re “redesigning” the complete freshman program.</p>
<p>“Given the highly publicized circumstances surrounding our main stage commencement program, university leadership has determined that it is best to excuse our external speakers and honorees from participating in this year’s ceremony,” it said in an announcement Friday published, unsigned statement from the university.  “We have spoken with this exceptional group and hope to award these honorary degrees at a future commencement or other academic ceremony.”</p>
<p>Chu was scheduled to present the keynote address on the May 10 ceremony.  He graduated from the university in 2003 and has since directed movies corresponding to &#8220;Crazy Rich Asians&#8221; and &#8220;Wicked,&#8221; an adaptation of the Broadway musical scheduled to hit theaters last yr.</p>
<p>More than 65,000 individuals are expected on campus at first, including 19,000 graduates.</p>
<p>“Although this should be a time of celebration for my family, friends, professors and classmates, anti-Muslim and anti-Palestinian voices have subjected me to a campaign of racist hatred because of my uncompromising belief in human rights for all,” Tabassum said in an announcement earlier this week.</p>
</div>
<p><em>image credit : www.mercurynews.com</em></p>
]]></content:encoded>
					
		
		
		<media:content url="https://www.mercurynews.com/wp-content/uploads/2024/04/sjm-eech-Canceled_187709719.jpg?w=1024&#038;h=682" medium="image"></media:content>
	</item>
	</channel>
</rss>
